BioNexus Launches BGLC 1Lab Pilot for GeneMatrix Workflows at MRNA Scientific
Availability is limited to the controlled pilot; release beyond it requires development, validation and applicable approvals.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BioNexus (Nasdaq: BGLC) introduced its BGLC 1Lab laboratory workflow product through a controlled GeneMatrix-focused pilot at subsidiary MRNA Scientific. BioNexus has built GeneMatrix Enterprise and completed internal workflow testing. The pilot in Penang, Malaysia, will evaluate traceability and staff review before wider deployment.
Clinical release remains subject to validation and security, privacy, regulatory and management reviews. BioNexus plans to integrate Ruanyun Edai Technology’s CogniAI document-processing platform after the anticipated closing of their Malaysian license agreement. That agreement remains subject to technology delivery, written acceptance, due diligence and required approvals; commercial deployment can begin only after closing.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Minor pointGeneMatrix Enterprise has been built, with internal workflow testing completed.
- Minor point. Forward-looking: it has not happened yet and may not happen.CogniAI integration is planned after the anticipated closing of the Malaysian license agreement with Ruanyun.
Negative
- Moderate pointRuanyun license closing requires technology delivery, written acceptance, due diligence and required approvals before commercial deployment.
- Minor point. Forward-looking: it has not happened yet and may not happen.Availability is limited to the controlled pilot; wider release requires development, validation and applicable approvals.
- Minor point. Forward-looking: it has not happened yet and may not happen.GeneMatrix Enterprise clinical release requires validation and applicable security, privacy, regulatory and management reviews.
- Minor point. Forward-looking: it has not happened yet and may not happen.Report Q&A release remains subject to clinical review, validation and regulatory assessment.
Historical Context
-
License terms included share consideration and a 10% technology-receipts royalty; closing remained conditional.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
large language models technical
laboratory information management system technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Product mini-site presents designs for customer reporting, private AI Q&A and agentic workflows; CogniAI integration would extend document processing
KUALA LUMPUR, Malaysia, Nov. 03, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC) ("BioNexus" or the "Company") today introduced BGLC 1Lab, its laboratory workflow product, and announced its initial launch as a controlled GeneMatrix-focused pilot at its MRNA Scientific Sdn. Bhd. subsidiary. A dedicated product mini-site is available at www.bionexusgenelab.com/1lab.
1Lab is designed to connect clinic orders, specimen reception, bench activity, scientific review and report delivery in one traceable record. The workflow design links each step to accountable staff and makes a test’s progress and exceptions visible.
| “We are in a transition phase in our healthcare business, toward services that can integrate with increasingly autonomous AI. We believe an important part of AI’s next phase of growth will come from connecting advances in large language models with the data and workflows needed to deliver useful services. We are developing 1Lab around laboratory operations, customer reporting and private AI, with qualified professionals retaining responsibility for laboratory and clinical decisions.” Sam Tan, Chief Executive Officer of BioNexus Gene Lab Corp. |
Starting with GeneMatrix
BioNexus has built an enterprise version of GeneMatrix, the software behind its blood-based genomic screening, and completed internal workflow testing. The 1Lab pilot at MRNA Scientific’s laboratory in Penang, Malaysia, focuses on connecting that analysis with the surrounding operational workflow.
The pilot will evaluate traceability and staff review before wider deployment. Clinical release of GeneMatrix Enterprise remains subject to validation and applicable security, privacy, regulatory and management reviews.
Secure reporting and private AI Q&A
The reporting system is designed to give referring clinics and authorized customers secure web and mobile access to released laboratory reports. That design includes viewing and downloading the current report, clear identification of corrected versions and retention of the report history. Patient access would follow clinician review and the laboratory’s release policy.
Private AI Q&A is designed to help customers understand their own reports in plain language. The Q&A design grounds answers in the exact released report version and approved explanatory material, with supporting references and limits on questions those sources cannot answer. Clinical interpretation and follow-up remain with the clinician. Release of report Q&A remains subject to clinical review, validation and regulatory assessment.
Agentic AI under laboratory control
1Lab’s AI design starts with staff-requested assistance: reading requisitions, drafting clinic messages and retrieving approved procedures. Source checks and named-person review govern each draft. More autonomous agent workflows are a longer-term development direction; specimen acceptance, run decisions, result verification and report authorization remain with authorized staff.
1Lab’s private and sovereign AI design centers on institutional control over model operation, data processing and access. It covers local hardware and institutionally managed computing capacity. For Malaysian deployments, design requirements include domestic hosting of personal data and exclusion of laboratory and patient records from public AI services and shared-model training.
CogniAI integration
Following the anticipated closing of the previously announced Malaysian license agreement with Ruanyun Edai Technology Inc. (Nasdaq: RYET) ("Ruanyun"), BioNexus intends to integrate Ruanyun’s CogniAI document-intelligence platform into 1Lab. CogniAI would provide document recognition, classification and extraction for 1Lab’s reading agents.
The document-processing integration would support GeneMatrix report-access and companion development; report Q&A requires separate source-grounding, validation and release controls.
The October 5, 2026 license agreement with Ruanyun remains subject to technology delivery, written acceptance, due diligence and required approvals. Commercial deployment can begin only after closing.
Connecting laboratories and clinics
MarketsandMarkets estimates the worldwide laboratory information management system market, which spans all industries and includes software, services and support, at US
Initial availability is limited to the controlled MRNA Scientific pilot. Release beyond the pilot, including agent, API and patient features, is subject to development, validation and applicable approvals. The mini-site includes designs shown with demonstration data. Clinics, laboratories and potential partners can explore 1Lab at www.bionexusgenelab.com/1lab or contact sales@bionexusgenelab.com.
¹ MarketsandMarkets, “Laboratory Information Management System (LIMS) Market – Global Forecast to 2031,” September 2026.
² Ministry of Health Malaysia, Health Facts 2025.
About BioNexus Gene Lab Corp.
BioNexus Gene Lab Corp. (Nasdaq: BGLC) is a technology-focused company operating across biotechnology, precision diagnostics and specialty materials. Through its subsidiaries, investments and licensing arrangements, the Company is developing new healthcare and life-science businesses alongside its established operations.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include the 1Lab pilot and wider release; GeneMatrix integration and validation; agentic workflows, customer reporting, private AI Q&A and related access features; private and sovereign AI deployment; CogniAI delivery, acceptance, closing and integration; the transition toward services integrating with increasingly autonomous AI; management’s view of future AI growth; industry-market projections; and adoption and commercialization beyond MRNA Scientific.
Actual results may differ materially because of development and integration difficulties; AI output errors and model or host performance; validation, cybersecurity, privacy, data-residency and healthcare regulatory requirements; technology delivery, acceptance, due diligence and closing conditions; intellectual-property and third-party rights; implementation resources and funding; competition and customer adoption; and other risks in the Company’s latest Form 10-K, subsequent Forms 10-Q and other SEC filings. Third-party market estimates have not been independently verified by the Company and are subject to differing definitions and forecasting assumptions. The pilot does not establish clinical validation or assure commercial availability, customer contracts or revenue. Forward-looking statements speak only as of the date made. BioNexus undertakes no obligation to update them except as required by law.
Investor Relations and Corporate Communications
BioNexus Gene Lab Corp.
ir@bionexusgenelab.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What is BioNexus testing in the BGLC 1Lab pilot?
The controlled pilot at MRNA Scientific’s laboratory in Penang, Malaysia, will evaluate traceability and staff review before wider deployment. It focuses on connecting GeneMatrix analysis with the surrounding laboratory operational workflow.
Will BGLC 1Lab AI make laboratory or clinical decisions?
Authorized staff retain responsibility for specimen acceptance, run decisions, result verification and report authorization. The initial AI design uses staff-requested assistance governed by source checks and named-person review. More autonomous agent workflows remain a longer-term development direction, while clinical interpretation and follow-up remain with clinicians.
How does BioNexus plan to protect patient data in Malaysian 1Lab deployments?
The design requirements call for domestic hosting of personal data and exclusion of laboratory and patient records from public AI services and shared-model training. The private AI design centers on institutional control over model operation, data processing and access; these are design requirements, not a statement of completed deployment.